Revelation Biosciences

REVB

Market cap $5.34M

SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced it has successfully reached a quorum for its Special Meeting scheduled for December 3, 2025. As a reminder, if you have not yet voted you have until 11:59pm ET tomorrow, December 2, 2025, to vote.

SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced successful submission and acceptance of the end-of-phase 1 meeting package to FDA and that the company is on track to hold the meeting later this year. The primary purpose of this meeting is to establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI).

SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 6, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and nine months ended September 30, 2025. Corporate Highlights Announced Groundbreaking Top-line Results from PRIME Clinical Study Received gross proceeds of $9.6 million from warrant inducement in September 2025 "The outstanding PRIME data and subsequent financing validate Gemini's potential and places the company on solid footing to advance the next phase of development," said James Rolke, Chief Executive Officer of Revelation.

SAN DIEGO, CA / ACCESS Newswire / October 29, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the October 15, 2025 Special Meeting of Stockholders of Revelation Biosciences, Inc. (the "Company"), which was adjourned to October 29, 2025 has been canceled due to technical difficulty outside of the Company's control with stockholders being unable to vote all of their shares. The Company has decided to cancel the adjourned Special Meeting scheduled for today, October 29, at 12pm ET and to set a new record date of October 29, 2025 for a new Special Meeting of Stockholders to take place on December 3, 2025.

SAN DIEGO, CA / ACCESS Newswire / October 15, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced that the Company as a result of insufficient shares present it has adjourned its 2025 Special Meeting of Stockholders (the "Special Meeting") originally convened on October 15, 2025 to allow additional time for stockholders to vote on the proposals described in the Company's proxy materials. The meeting will reconvene on October 29, 2025, at 12:00 p.m.

SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,355,000 shares of common stock, issued by the Company on May 29, 2025 (the "Existing Warrants"), at the existing exercise price of $2.20 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-1 (File No.

- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - Data discussion webcast/conference call will be held at 8:30 am Eastern Time SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, will host a corporate update webcast/conference call (details below) at 8:30 am Eastern Time to review groundbreaking activity data from its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease (CKD) patients. The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met.

SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, wants to remind you of our September 10th webcast at 8:30 am Eastern Time, which can be accessed here or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use the participant access code 289672. We look forward to reviewing the data with you tomorrow morning.

- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - Data discussion webcast/conference call will be held on Wednesday, September 10th at 8:30 am Eastern Time SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced positive safety and activity data for its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease (CKD) patients. The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met.

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team con.